Share This Article:

Early Diagnosis of Cardiac Toxicity Related to Antineoplastic Treatment

Abstract Full-Text HTML Download Download as PDF (Size:144KB) PP. 161-166
DOI: 10.4236/jct.2011.22019    4,394 Downloads   7,679 Views   Citations

ABSTRACT

Background: breast cancer because of radiotherapy and/or chemotherapy causes cardiac disease, often it occurs on women just affected by hypertension and/or diabetes. All these conditions may affect left ventricular (LV) geometry, mass and diastolic function. The purpose of this study is to early detect these affections to improve heart failure prevention. Patients and methods: 134 women, affected by breast cancer, underwent to conventional transthoracic echocar-diography (TTE) and pulse wave tissue Doppler imaging (PW-TDI). A control group (CG) of 80 women unaffected by breast cancer, hypertension and diabetes was enrolled. Results: 54 of 134 women (40.2%), were affected by hypertension or diabetes too (Prone Group = PG), 8 by both, 80 (59.8%) were free (FG). Mean age of all patients was 45.4 years. The rates of LV eccentric hypertrophy and LV distolic dysfunction were statistically significant higher on FG group than controls, and on PG group than FG group. Conclusions: an abnormal LV diastolic function is more common among women affected by breast cancer after treatment than in general population, the same for LV eccentric hypertrophy but at a lower rate. 40% of women were affected by hypertension, diabetes or both, and as expected they have a higher rate of LV eccentric hypertrophy and diastolic dysfunction. This high prevalence of LV eccentric hypertrophy and diastolic dysfunction, on asymptomatic women, affected by breast cancer, is a predictor of heart failure; Doppler-echo techniques may be helpful in early diagnosis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Maiello, R. Sharma, M. Ciccone, H. Reddy and P. Palmiero, "Early Diagnosis of Cardiac Toxicity Related to Antineoplastic Treatment," Journal of Cancer Therapy, Vol. 2 No. 2, 2011, pp. 161-166. doi: 10.4236/jct.2011.22019.

References

[1] M. N. Levine and T. Whelan, “Adjuvant Chemotherapy for Breast Cancer—30 Years Later,” The New England Journal of Medicine, Vol. 355, No. 18, 2006, pp. 1920-1922. doi:10.1056/NEJMe068204
[2] Early Breast Cancer Trialists’ Collaborative Group, “Effects of Radiotherapy and Surgery in Early Breast Cancer. An Overview of the Randomized Trials,” The New England Journal of Medicine, Vol. 333, No. 22, 1995, pp. 1444-1455. doi:10.1056/NEJM199511303332202
[3] M. J. Hooning, et al., “Long-Term Risk of Cardiovascular Disease in 10-year Survivors of Breast Cancer,” Journal of the National Cancer Institute, Vol. 99, No. 5, 2007, pp. 365-375. doi:10.1093/jnci/djk064
[4] T. Hampton, “Cancer Therapy Can Be Hard on the Heart: Researchers Aim to Explain—and Avoid—Cardiotoxicity,” Journal of the American Medical Association, Vol. 303, No. 11, 2010, pp. 1019-1020. doi:10.1001/jama.2010.269
[5] P. A. Heidenreich, et al., “Diastolic Dysfunction after Mediastinal Irradiation,” American Heart Journal, Vol. 150, No. 5, 2005, pp. 977-982. doi:10.1016/j.ahj.2004.12.026
[6] M. T. Meinardi, et al., “Evaluation of Long Term Cardiotoxicity after Epirubicin Containing Adjuvant Chemotherapy and Locoregional Radiotherapy for Breast Cancer Using Various Detection Techniques,” Heart, Vol. 88, No. 1, 2002, pp. 81-82. doi:10.1136/heart.88.1.81
[7] J. Alexander, et al., “Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide Angiocardiography,” The New England Journal of Medicine, Vol. 300, No. 6, 1979, pp. 278-283. doi:10.1056/NEJM197902083000603
[8] R. G. Schwartz, et al., “Congestive Heart Failure and Left Ventricular Dysfunction Complicating Doxorubicin Therapy. Seven-Year Experience Using Serial Radionuclide Angiocardiography,” American Journal of Medicine, Vol. 82, No. 6, 1987, pp. 1109-1118. doi:10.1016/0002-9343(87)90212-9
[9] L. Mosca, et al., “Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update,” Journal of the American College of Cardiology, Vol. 49, No. 11, 2007, pp. 1230-1250. doi:10.1016/j.jacc.2007.02.020
[10] W. I. Ganz, et al., “Review of Tests for Monitoring Doxorubicin-Induced Cardiomyopathy,” Oncology, Vol. 53, No. 6, 1996, pp. 461-470. doi:10.1159/000227621
[11] R. Yancik, et al., “Effect of Age and Comorbidity in Postmenopausal Breast Cancer Patients Aged 55 Years and Older,” Journal of the American Medical Association, Vol. 285, No. 7, 2001, pp. 885-892. doi:10.1001/jama.285.7.885
[12] C. P. Appleton, et al., “Doppler Evaluation of Left and Right Ventricular Diastolic Function: A Technical Guide for Obtaining Optimal Flow Velocity Recordings,” Journal of the American Society of Echocardiography, Vol. 10, No. 3, 1997, pp. 271-292. doi:10.1016/S0894-7317(97)70063-4
[13] J. W. Ha, et al., “Triphasic Mitral Inflow Velocity with Middiastolic Filling: Clinical Implications and Associated Echocardiographic Findings,” Journal of the American Society of Echocardiography, Vol. 17, No. 5, 2004, pp. 428-431. doi:10.1016/j.echo.2004.02.007
[14] S. F. Nagueh, et al., “Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography,” Journal of the American Society of Echocardiography, Vol. 22, No. 2, 2009, pp. 107-133. doi:10.1016/j.echo.2008.11.023
[15] R. B. Devereux and N. Reichek, “Echocardiographic Determination of Left Ventricular Mass in Man. Anatomic Validation of the Method,” Circulation, Vol. 55, No. 4, 1977, pp. 613-618.
[16] H. W. Hense, et al., “The Associations of Body Size and Body Composition with Left Ventricular Mass: Impacts for Indexation in Adults,” Journal of the American College of Cardiology, Vol. 32, No. 2, 1998, pp. 451-457. doi:10.1016/S0735-1097(98)00240-X
[17] G. P. Aurigemma, M. R. Zile and W. H. Gaasch, “Contractile Behavior of the Left Ventricle in Diastolic Heart Failure: With Emphasis on Regional Systolic Function,” Circulation, Vol. 113, No. 2, 2006, pp. 296-304. doi:10.1161/CIRCULATIONAHA.104.481465
[18] G. de Simone, et al., “Evaluation of Concentric Left Ventricular Geometry in Humans: Evidence for Age-Related Systematic Underestimation,” Hypertension, Vol. 45, No. 1, 2005, pp. 64-68.
[19] D. J. Sahn, et al., “Recommendations Regarding Quantitation in M-mode Echocardiography: Results of a Survey of Echocardiographic Measurements,” Circulation, Vol. 58, No. 6, 1978, pp. 1072-1083.
[20] M. M. Redfield, et al., “Burden of Systolic and Diastolic Ventricular Dysfunction in the Community: Appreciating the Scope of the Heart Failure Epidemic,” Journal of the American Society of Echocardiography, Vol. 289, No. 2, 2003, pp. 194-202. doi:10.1001/jama.289.2.194
[21] N. B. Schiller, et al., “Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms,” Journal of the American Society of Echocardiography, Vol. 2, No. 5, 1989, pp. 358-367.
[22] R. A. Nishimura, and A. J. Tajik, “Evaluation of Diastolic Filling of Left Ventricle in Health and Disease: Doppler Echocardiography is the Clinician’s Rosetta Stone,” Journal of the American College of Cardiology, Vol. 30, No. 1, 1997, pp. 8-18.
[23] J. Dubin, et al., “Comparative Accuracy of Doppler Echocardiographic Methods for Clinical Stroke Volume Determination,” American Heart Journal, Vol. 120, No. 1, 1990, pp. 116-123. doi:10.1016/0002-8703(90)90168-W
[24] S. R. Ommen, et al., “Clinical Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Left Ventricular Filling Pressures: A Comparative Simultaneous Doppler-Catheterization Study,” Circulation, Vol. 102, No. 15, 2000, pp. 1788-1794.
[25] A. Ganau, et al., “Patterns of Left Ventricular Hypertrophy and Geometric Remodeling in Essential Hypertension,” Journal of the American College of Cardiology, Vol. 19, No. 7, 1992, pp. 1550-1558. doi:10.1016/0735-1097(92)90617-V
[26] J. J. Doyle, et al., “Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study,” Journal of Clinical Oncology, Vol. 23, No. 34, 2005, pp. 8597-8605. doi:10.1200/JCO.2005.02.5841
[27] E. A. Perez, et al., “Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients with Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial,” Journal of Clinical Oncology, Vol. 22, No. 18, 2004, pp. 3700-3704. doi:10.1200/JCO.2004.03.516
[28] E. T. Yeh, “Cardiotoxicity Induced by Chemotherapy and Antibody Therapy,” Annual Review of Medicine, Vol. 57, 2006, pp. 485-498. doi:10.1146/annurev.med.57.121304.131240
[29] D. Lebrecht, et al., “Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy,” Circulation, Vol. 108, No. 19, 2003, pp. 2423-2429. doi:10.1161/01.CIR.0000093196.59829.DF
[30] M. S. Anscher and Z. Vujaskovic, “Mechanisms and Potential Targets for Prevention and Treatment of Normal Tissue Injury after Radiation Therapy,” Seminars in Oncology, Vol. 32, No. 2 (Supplement), 2005, pp. S86-91. doi:10.1053/j.seminoncol.2005.03.015
[31] D. M. Lloyd-Jones, et al., “Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age,” Circulation, Vol. 113, No. 6, 2006, pp. 791-798. doi:10.1161/CIRCULATIONAHA.105.548206
[32] P. M. Ridker, et al., “Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women: The Reynolds Risk Score,” Journal of the American Society of Echocardiography, Vol. 297, No. 6, 2007, pp. 611-619. doi:10.1001/jama.297.6.611

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.